{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:43:45Z","timestamp":1777045425474,"version":"3.51.4"},"reference-count":55,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T00:00:00Z","timestamp":1341792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>To investigate the anti-carcinogenic effects of Atorvastatin (Atorva) on a rat bladder carcinogenesis model with N-butyl-N-(4-hydroxibutil)nitrosamine (BBN), four male Wistar rat groups were studied: (1) Control: vehicle; (2) Atorva: 3 mg\/kg bw\/day; (3) Carcinogen: BBN (0.05%); (4) Preventive Atorva: 3 mg\/kg bw\/day Atorva + BBN. A two phase protocol was used, in which the drug and the carcinogen were given between week 1 and 8 and tumor development or chemoprevention were expressed between week 9 and 20, when the bladders were collected for macroscopic, histological and immunohistochemical (p53, ki67, CD31) evaluation. Serum was assessed for markers of inflammation, proliferation and redox status. The incidence of bladder carcinoma was: control 0\/8 (0%); Atorva 0\/8 (0%); BBN 13\/20 (65%) and Atorva + BBN 1\/8 (12.5%). The number and volume of tumors were significantly lower in the Atorva + BBN group, with a marked reduction in hyperplasia, dysplasia and carcinoma in situ lesions. An anti-proliferative, anti-inflammatory and antioxidant profile was also observed in the preventive Atorva group. p53 and ki67 immunostaining were significantly increased in the BBN-treated rats, which was prevented in the Atorva + BBN group. No differences were found for CD31 expression. In conclusion, Atorvastatin had a clear inhibitory effect on bladder cancer development, probably due to its antioxidant, anti-proliferative and anti-inflammatory properties.<\/jats:p>","DOI":"10.3390\/ijms13078482","type":"journal-article","created":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T11:01:02Z","timestamp":1341831662000},"page":"8482-8499","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Chemopreventive Efficacy of Atorvastatin against Nitrosamine-Induced Rat Bladder Cancer: Antioxidant, Anti-Proliferative and Anti-Inflammatory Properties"],"prefix":"10.3390","volume":"13","author":[{"given":"Belmiro","family":"Parada","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology & Experimental Therapeutics, Institute of Biomedical Research on Light and Image, Medicine Faculty, Coimbra University, Coimbra, 3000-548, Portugal"},{"name":"Department of Urology & Renal Transplantation, Coimbra University Hospital, Coimbra, 3000-075, Portugal"}]},{"given":"Fl\u00e1vio","family":"Reis","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology & Experimental Therapeutics, Institute of Biomedical Research on Light and Image, Medicine Faculty, Coimbra University, Coimbra, 3000-548, Portugal"}]},{"given":"\u00c2ngela","family":"Pinto","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology & Experimental Therapeutics, Institute of Biomedical Research on Light and Image, Medicine Faculty, Coimbra University, Coimbra, 3000-548, Portugal"}]},{"given":"Jos\u00e9","family":"Sereno","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology & Experimental Therapeutics, Institute of Biomedical Research on Light and Image, Medicine Faculty, Coimbra University, Coimbra, 3000-548, Portugal"}]},{"given":"Maria","family":"Xavier-Cunha","sequence":"additional","affiliation":[{"name":"Service of Anatomic Pathology, Coimbra University Hospital, Coimbra, 3000-075, Portugal"}]},{"given":"Paula","family":"Neto","sequence":"additional","affiliation":[{"name":"Service of Anatomic Pathology, Coimbra University Hospital, Coimbra, 3000-075, Portugal"}]},{"given":"Petronila","family":"Rocha-Pereira","sequence":"additional","affiliation":[{"name":"Research Centre for Health Sciences, Beira Interior University, Covilh\u00e3, 6201-506, Portugal"}]},{"given":"Alfredo","family":"Mota","sequence":"additional","affiliation":[{"name":"Department of Urology & Renal Transplantation, Coimbra University Hospital, Coimbra, 3000-075, Portugal"}]},{"given":"Arnaldo","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Department of Urology & Renal Transplantation, Coimbra University Hospital, Coimbra, 3000-075, Portugal"}]},{"given":"Frederico","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology & Experimental Therapeutics, Institute of Biomedical Research on Light and Image, Medicine Faculty, Coimbra University, Coimbra, 3000-548, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2012,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eursup.2008.04.001","article-title":"Bladder cancer: A major public health issue","volume":"7","author":"Grasso","year":"2008","journal-title":"Eur. Urol. Suppl"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann. Oncol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: Epidemiology, staging, grading and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.10.040","article-title":"Muscle-invasive urothelial carcinoma of the bladder","volume":"69","author":"Malkowicz","year":"2007","journal-title":"Urology"},{"key":"ref_6","first-page":"4","article-title":"The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies","volume":"66","author":"Zeegers","year":"2000","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1023\/B:CACO.0000007962.19066.9c","article-title":"Occupation and bladder cancer among men in Western Europe","volume":"14","author":"Kogevinas","year":"2003","journal-title":"Cancer Causes Contr"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000108298","article-title":"The genetics of bladder cancer: A cytogeneticist\u2019s perspective","volume":"118","author":"Wolff","year":"2007","journal-title":"Cytogenet. Genome Res"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CEJ.0b013e32830c8d44","article-title":"Alcohol, coffee, and bladder cancer risk: A review of epidemiological studies","volume":"18","author":"Pelucchi","year":"2009","journal-title":"Eur. J. Cancer Prev"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00284372","article-title":"Stages of transformation in the development of Nbutyltransitional cell carcinomas in the urinary bladder of rats","volume":"87","author":"Kunze","year":"1976","journal-title":"Z. Krebsforsch. Klin. Onkol"},{"key":"ref_11","first-page":"2","article-title":"Experimental bladder carcinogenesis-rodent models","volume":"28","author":"Oliveira","year":"2006","journal-title":"Exp. Oncol"},{"key":"ref_12","first-page":"81","article-title":"Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl) nitrosamine","volume":"67","author":"Fukushimam","year":"1976","journal-title":"Gann"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4161\/cbt.7.1.5134","article-title":"The effectiveness of retinoic acid treatment in bladder cancer: Impact on recurrence, survival and TGF-alpha and VEGF as end-point biomarkers","volume":"7","author":"Hameed","year":"2008","journal-title":"Canc. Biol. Ther"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1464-410X.2010.09326.x","article-title":"Inhibition of bladder tumor growth by sirolimus in an experimental carcinogenesis model","volume":"107","author":"Parada","year":"2011","journal-title":"BJU Int"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.4161\/cbt.8.17.9199","article-title":"Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis","volume":"8","author":"Parada","year":"2009","journal-title":"Cancer Biol.Ther"},{"key":"ref_16","first-page":"930","article-title":"Statins and cancer prevention","volume":"5","author":"Demierre","year":"2005","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1440-1681.2007.04565.x","article-title":"Cholesterol, statins and cancer","volume":"34","author":"Brown","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2007.11.036","article-title":"Statins in tumor suppression","volume":"260","author":"Sassano","year":"2008","journal-title":"Cancer Lett"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Ann. Rev. Pharmacol. Toxicol"},{"key":"ref_20","first-page":"18","article-title":"Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as anti-inflammatory agents?","volume":"109","author":"Libby","year":"2004","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/hq0202.104081","article-title":"Cellular antioxidant effects of atorvastatin in vitro and in vivo","volume":"22","author":"Wassmann","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1440-1681.2004.04010.x","article-title":"Anti-apoptotic effect of atorvastatin, a 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor, on cardiac myocytes through protein kinase C activation","volume":"31","author":"Tanaka","year":"2004","journal-title":"Clin. Exp. Pharmacol. Physiol"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156800905774932824","article-title":"Anti-angiogenic and anti-inflammatory effects of statins: Relevance to anti-cancer therapy","volume":"5","author":"Dulak","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/gast.2002.31093","article-title":"3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis","volume":"122","author":"Kusama","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11934-008-0034-z","article-title":"Rationale for statins in the chemoprevention of prostate cancer","volume":"9","author":"Hamilton","year":"2008","journal-title":"Curr. Urol. Rep"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/CAD.0b013e328304ae19","article-title":"In vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: Potential implications in acute leukemia","volume":"19","author":"Calabro","year":"2008","journal-title":"Anti-cancer Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.cad.0000215058.85813.02","article-title":"Synergistic antimyeloma effects of zoledronate and simvastatin","volume":"17","author":"Schmidmaier","year":"2006","journal-title":"Anti-cancer Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.urology.2005.06.075","article-title":"Atorvastatin: A potential chemopreventive agent in bladder cancer","volume":"66","author":"Kamat","year":"2005","journal-title":"Urology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bjc.6601566","article-title":"Statin use and cancer risk in the General Practice Research Database","volume":"90","author":"Kaye","year":"2004","journal-title":"Br. J . Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/bjs.4391","article-title":"Hyperlipidaemia is positively correlated with lymph node metastasis in men with early gastric cancer","volume":"91","author":"Kitayama","year":"2004","journal-title":"Br. J. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10557-007-6036-0","article-title":"The cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation","volume":"21","author":"Manickavasagam","year":"2007","journal-title":"Cardiovasc. Drugs. Ther"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1074248407312839","article-title":"Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat","volume":"13","author":"Birnbaum","year":"2008","journal-title":"J. Cardiovasc. Pharmacol. Ther"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cvr\/cvp005","article-title":"Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects","volume":"82","author":"Schmechel","year":"2009","journal-title":"Cardiovasc. Res"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0163-7258(03)00055-X","article-title":"The lipid and non-lipid effects of statins","volume":"99","author":"Wierzbicki","year":"2003","journal-title":"Pharmacol. Ther"},{"key":"ref_35","first-page":"10","article-title":"The statins as anticancer agents","volume":"9","author":"Chan","year":"2003","journal-title":"Clin. Canc. Res"},{"key":"ref_36","first-page":"4901","article-title":"HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model","volume":"29","author":"Bababeygy","year":"2009","journal-title":"Anticancer Res"},{"key":"ref_37","first-page":"1817","article-title":"Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells","volume":"24","author":"Bocsi","year":"2004","journal-title":"Anticancer Res"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/309464a0","article-title":"Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumors","volume":"309","author":"Fujita","year":"1984","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/01.ju.0000088670.02905.78","article-title":"The role of Ras superfamily proteins in bladder cancer progression","volume":"170","author":"Oxford","year":"2003","journal-title":"J .Urol"},{"key":"ref_40","first-page":"1105","article-title":"Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation","volume":"30","author":"Acimovic","year":"2010","journal-title":"Anticancer Res"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug Discov"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/01.RES.0000269334.42814.d2","article-title":"Peroxisome proliferators-activated receptors mediate pleiotropic actions of statins","volume":"100","author":"Paumelle","year":"2007","journal-title":"Circ. Res"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc1254","article-title":"Peroxisome proliferators-activated receptors and cancer: Complex stories","volume":"4","author":"Michalik","year":"2004","journal-title":"Nat. Rev"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4161\/cbt.8.7.7853","article-title":"Peroxisome proliferator-activated receptor gamma in bladder cancer: A promising therapeutic target","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol. Ther"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-07-0242","article-title":"Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice","volume":"13","author":"Zheng","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.4161\/cbt.214","article-title":"Chemoprevention strategies using NSAIDs and COX-2 inhibitors","volume":"2","author":"Keller","year":"2003","journal-title":"Canc. Biol. Ther"},{"key":"ref_47","first-page":"46","article-title":"Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31","volume":"6","author":"Mansuri","year":"2011","journal-title":"Libyan. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.urolonc.2010.03.021","article-title":"International Study-Initiative on Bladder Cancer (ISBC). p53 immunohistochemistry in bladder cancer- a new approach to an old question","volume":"28","author":"Goebell","year":"2010","journal-title":"Urol. Oncol"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-8140(98)00033-4","article-title":"The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy","volume":"49","author":"Lara","year":"1998","journal-title":"Radiother. Oncol"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/ijc.23192","article-title":"Chronic inflammation and oxidative stress in human carcinogenesis","volume":"121","author":"Federico","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lfs.2008.04.010","article-title":"Antioxidant effects of green tea and its polyphenols on bladder cells","volume":"83","author":"Coyle","year":"2008","journal-title":"Life Sci"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12012-009-9054-2","article-title":"Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic sports doping","volume":"9","author":"Piloto","year":"2009","journal-title":"Cardiovasc. Toxicol"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/sj.bjc.6601748","article-title":"A population-based study of immunohistochemical detection of p53 alteration in bladder cancer","volume":"90","author":"Kelsey","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1309\/LTFU3UUMBY095HUM","article-title":"Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: The role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters","volume":"122","author":"Luque","year":"2004","journal-title":"Am. J. Clin. Pathol"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2407-7-135","article-title":"Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice","volume":"7","author":"Taylor","year":"2007","journal-title":"BMC Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/13\/7\/8482\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:51:11Z","timestamp":1760219471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/13\/7\/8482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,9]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,7]]}},"alternative-id":["ijms13078482"],"URL":"https:\/\/doi.org\/10.3390\/ijms13078482","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,9]]}}}